Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.
XVIVO Perfusion AB has announced a delay in the CE approval for its heart perfusion solution, part of its heart preservation technology, due to additional consultation required by EU authorities. Despite this setback, the company’s Heart Assist Transport system has received CE approval, and recent trial results show significant improvements in patient survival, highlighting the technology’s potential impact on heart transplantation.
The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO Perfusion AB is a medical technology company focused on extending the life of major organs to enhance transplantation outcomes. Headquartered in Gothenburg, Sweden, and listed on Nasdaq Stockholm, XVIVO provides innovative solutions that push the boundaries of transplantation medicine.
YTD Price Performance: -54.23%
Average Trading Volume: 112,414
Technical Sentiment Signal: Sell
Current Market Cap: SEK7.05B
Learn more about XVIVO stock on TipRanks’ Stock Analysis page.